Member Info for Fredd1eboy

Guess you're right CH. We are at the mercy of scant trading. A £10 sell could probably wipe off £1m of our value "tongue in cheek". Why is our so so low, I ask myself. Is it...fear...disinterest...I guess a combination. But all are issues that Olav Hellebo can tackle with good pr. If and I hope "If" he is working miracles behind the scenes I'm happy to support his salary. . but as far as his bonus is concerened, it should relate to shareholder value and not leach on the backs of the scientists efforts. Thank goodness we are not in the sights of the short termed as we would be worth nothing by now

No arguing now. Guess we are all so ****ed off with the sp, we are looking for a whipping post. Don't knock each other....it's Hellebo that should be our target. Guess he's never heard of TQM and the importance of shareholder value. His scientific/manufacturing process teams with be fully conversant with the spc element but Hellebo doesn't have a clue about 'hearts and minds'. On a scale of 1 to 10 my faith in him is at 1. He has 1 month to get his act together before he drops to zero. Its a bloody disgrace and if he gets rewarded with share options at 1p, then Woodford, Evans and the Welsh Gov Agency needs their heads tested. I don't k ow if I can make the AGM but I urge all long suffering shareholders to attend and vent your feelings there and not at each other here

Just returned to UK. Feeks like added insult to injury. Haven't received any agm paperwork from Reneuron, neither has the missus. Anyone else been forgotten. Really feel like attending and voting against renumeration package. as 2/3 of BOD appear to me to be "blood sucking" leaches. Reward the scientists and "deal makers, if there are any" sod the rest.

Hopefully all our treatment lines for the criteria but CLI in particular.... .here's hoping....  Access to new medicines Summary You asked for a briefing on the Accelerated Access Review (AAR). This note outlines background to the Review and summarises the final recommendations and Government responses to the report. A short summary of the Early Access to Medicines Scheme (EAMS) is also included. The AAR was an independent review commissioned by the Government to consider how to accelerate access to innovative medicines and medical technologies for NHS patients. The final AAR report was published in October 2016 and made a number of recommendations, highlighted in Box 1 of this note. The Government welcomed the review at the time it was published but has not yet issued an official response. However, there have been several Government actions in this area that implement some of the AAR recommendations. These relate to transferring the responsibility for the Commercial Medicines Unit to NHS England and the announcement of new funding for small and medium sized enterprises (SMEs) to develop and test new medicines and technologies. Several charitable and medical organisations have also welcomed the review recommendations. Accelerated Access Review Background The Accelerated Access Review (AAR) was an independent review commissioned by the Government in November 2014 to assess and make recommendations to the Government on how to accelerate access for NHS patients to innovative medicines and medical technologies. The Department of Health explained the aim of the review in the press release which announced the terms of reference for the review: The aim of the review is to ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations. This will help stimulate new investment, jobs and economic growth to support a stronger NHS. The review’s terms of reference show how it will explore opportunities to get innovative medicines, devices and diagnostics from the lab to NHS patients as quickly and safely as possible. It currently takes on average over a decade and can cost £1 billion to develop a new drug – from the early pre-clinical research right through to being available for patients. The review will make recommendations to accelerate this and tackle regulatory obstacles. Along with the terms of reference, the AAR announced the appointment of a Chair of the Review, Sir Hugh Taylor and the Head of the Advisory board, Professor Sir John Bell. The main themes and questions for the review were: establishing need, priorities and principles for innovation – how can we find a transparent way for innovators

Understood and agreed Drax. Best wishes. Fred

That kind of move would be appreciated by yours truly Drax but what's you're. ... Rationale? Timing and precipitation news flow?

Thanks ezik. A long way to go for me but well done to you. Best wishes. Freddie

I read market inefficies to include the "Reneuron Board"... You all have allowed the stock price to collapse without intervention. If your major benefactor Neil Woodford is showing faith in your technology (your scientists) why aren't you showing faith in the stock by investing in it. Or are you all just leaches. ..on the backs of the workers/investors....If so shame, on you all....lead from the front for goodness sake. You are all in the driving seat.. get out of first gear. Now, not when you return from your expensive holidays! When I managed in the automotive industry...poor performers were warned and if no improvement resulted, within a short time they were sent on a career development move.... "A boot up the arse and out the door"...Board directors included! "By way of example, ReNeuron, a leading clinical stage stem cell business, had a market capitalisation at period end of £54m. At its latest financial year end (31 March 2017), the company held £53m in cash on its balance sheet, meaning that the stock market is effectively ascribing a value of £1m to the future value of this company'sy world-class technology. This appears ludicrous, in my view, but it also serves as an effective demonstration of how market inefficiencies can lead to compelling long-term investment opportunities".

Always a Tuesday...looks like a mini bear trap made one pi think again

Always a Tuesday...looks like a mini bear trap made one pi think again

...should out out the short seller

Many thanks Fred

Would you kindly share the full Woodford post as I'm on route and signal cap. Best wishes. Fred

I hope you're right gibson. I'm just a humble retired engineer who invested heavily in biotechs in order to make a difference to suffering in the process of making some cash for retirement. As it stands three out of six bio companies have gone bust. The remainder I have lost heavily on. I am currently massively exposed to Reneuron and sick at the relentless shorting of the stock. I had hoped Olav Hellebo would have taken some damage limitation measures by now, but he chooses to make silly comments/jokes at meetings/conferences. He has to measure up along with the board, commencing with investing in the ship they are steaming. Captain, navigator, engineer, medical officer, Bursar must all take a position on the helm....etc etc

I have to agree that Olav is taking the mickey when he takes such a laissez-faire attitude to the time being taken, delays to date, cash flow (why isn't the new facility producing cell doses yet). Just goes on and on. In order to take Rene001 through phase 3 trials, we need a deal in place and at a reasonable cost. It should have been in place way before the sp got hammered down so low. It's also [pretty clear why directors haven't bought in yet. Unless I hear to the contrary, I smell a stinking rat and being exposed so much I'm cross, very cross.

Selling at 1.6p and insignificant purchases. I just hope it's due to poor pr management/disinterest and nothing more sinister. Guess we will be going for more funding in next few months. Unless we get a lift through good news we are going in like lambs to the slaughter. Come on Olav and earn your inflated salary.

Press release: First patient receives potential new treatment for wet age-related macular degeneration in London Project to Cure Blindness. London Monday 28 September: A pioneering trial of a new treatment derived from stem cells for people with ‘wet’ age-related macular degeneration (AMD) has commenced at Moorfields Eye Hospital following a successful operation on a patient. This first operation is a major milestone in the London Project to Cure Blindness, which was established 10 years ago with the aim of curing vision loss in patients with wet AMD, and is the result of a partnership between the hospital, the UCL Institute of Ophthalmology, and the National Institute for Health Research (NIHR). Pfizer Inc. joined the partnership [in 2009] with the goal of helping to turn the original idea into a potential therapy. The trial is investigating the safety and efficacy of transplanting eye cells (retinal pigment epithelium) derived from stem cells to treat people with sudden severe visual loss from wet AMD. These cells are used to replace those at the back of the eye that are diseased in AMD. This is done using a specially engineered patch inserted behind the retina in an operation lasting one to two hours. The first surgery was successfully performed on a patient last month and there have been no complications to date. The patient wishes to remain anonymous, but the team hope to determine her outcome in terms of initial visual recovery by early December (2015). “There is real potential that people with wet age-related macular degeneration will benefit in the future from transplantation of these cells,” says retinal surgeon Professor Lyndon Da Cruz from Moorfields Eye Hospital, who is performing the operations and is co-leading the London Project. The trial will recruit 10 patients in total over a period of 18 months. Each patient will be followed for a year to assess the safety and stability of the cells and whether there is an effect in restoring vision. Professor Pete Coffey of the UCL Institute of Ophthalmology, who is also co-leading the London Project, said: “We are tremendously pleased to have reached this stage in the research for a new therapeutic approach. Although we recognise this clinical trial focuses on a small group of AMD patients who have experienced sudden severe visual loss, we hope that many patients may benefit in the future.” Professor Sir Peng Tee Khaw, Director of the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, added: “We are delighted to be the site for this very exciting new clinical trial in stem cell therapy, which has the potential to give hope and make such a difference to the lives of people with blinding retinal conditions,”. Professor Philip J Luthert, Director of the UCL Institute of Ophthalmology, said: “The trial has shown the power of c

Hi Cadburyhill. More info C/o mol iii site relates to this trial Freddie http://clinicaltrials.gov/ct2/show/NCT01691261?term=pfizer&cond=AMD&cntry1=EU%3AGB&rank=2 however they failed to pick up on this http://clinicaltrials.gov/ct2/show/NCT03102138?term=pfizer&cond=AMD&cntry1=EU%3AGB&rank=1 relates overall to http://www.thelondonproject.org/ which has been discussed before in a previous life - but we'll not go there lol mol

Thanks CadburyHill Food for thought....I have taken the liberty of sharing on iii site. Let's hope our therapy works. Hopefully, we will get some news soon and positive

http://www.pharmaceutical-journal.com/20203325.article?utm_campaign=2482_PJ_daily_alert&utm_medium=email&utm_source=Pharmaceutical%20Journal